375 related articles for article (PubMed ID: 15032527)
1. Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example.
Rollinger JM; Haupt S; Stuppner H; Langer T
J Chem Inf Comput Sci; 2004; 44(2):480-8. PubMed ID: 15032527
[TBL] [Abstract][Full Text] [Related]
2. Discovering COX-inhibiting constituents of Morus root bark: activity-guided versus computer-aided methods.
Rollinger JM; Bodensieck A; Seger C; Ellmerer EP; Bauer R; Langer T; Stuppner H
Planta Med; 2005 May; 71(5):399-405. PubMed ID: 15931575
[TBL] [Abstract][Full Text] [Related]
3. 2D QSAR consensus prediction for high-throughput virtual screening. An application to COX-2 inhibition modeling and screening of the NCI database.
Baurin N; Mozziconacci JC; Arnoult E; Chavatte P; Marot C; Morin-Allory L
J Chem Inf Comput Sci; 2004; 44(1):276-85. PubMed ID: 14741037
[TBL] [Abstract][Full Text] [Related]
4. Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.
Hsu N; Cai D; Damodaran K; Gomez RF; Keck JG; Laborde E; Lum RT; Macke TJ; Martin G; Schow SR; Simon RJ; Villar HO; Wick MM; Beroza P
J Med Chem; 2004 Sep; 47(20):4875-80. PubMed ID: 15369391
[TBL] [Abstract][Full Text] [Related]
5. Fuzzy pharmacophore models from molecular alignments for correlation-vector-based virtual screening.
Renner S; Schneider G
J Med Chem; 2004 Sep; 47(19):4653-64. PubMed ID: 15341481
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa.
Krovat EM; Frühwirth KH; Langer T
J Chem Inf Model; 2005; 45(1):146-59. PubMed ID: 15667140
[TBL] [Abstract][Full Text] [Related]
7. Expanding the ChemGPS chemical space with natural products.
Larsson J; Gottfries J; Bohlin L; Backlund A
J Nat Prod; 2005 Jul; 68(7):985-91. PubMed ID: 16038536
[TBL] [Abstract][Full Text] [Related]
8. Optimization and validation of a docking-scoring protocol; application to virtual screening for COX-2 inhibitors.
Mozziconacci JC; Arnoult E; Bernard P; Do QT; Marot C; Morin-Allory L
J Med Chem; 2005 Feb; 48(4):1055-68. PubMed ID: 15715473
[TBL] [Abstract][Full Text] [Related]
9. Partially unified multiple property recursive partitioning (PUMP-RP) analyses of cyclooxygenase (COX) inhibitors.
Rao SN; Stockfisch TP
J Chem Inf Comput Sci; 2003; 43(5):1614-22. PubMed ID: 14502496
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Apr; 13(7):2459-68. PubMed ID: 15755648
[TBL] [Abstract][Full Text] [Related]
11. 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.
Ranatunge RR; Earl RA; Garvey DS; Janero DR; Letts LG; Martino AM; Murty MG; Richardson SK; Schwalb DJ; Young DV; Zemtseva IS
Bioorg Med Chem Lett; 2004 Dec; 14(24):6049-52. PubMed ID: 15546727
[TBL] [Abstract][Full Text] [Related]
12. Virtual screening strategies in drug discovery.
McInnes C
Curr Opin Chem Biol; 2007 Oct; 11(5):494-502. PubMed ID: 17936059
[TBL] [Abstract][Full Text] [Related]
13. Designing selective COX-2 inhibitors: molecular modeling approaches.
Trummlitz G; van Ryn J
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):550-61. PubMed ID: 12197313
[TBL] [Abstract][Full Text] [Related]
14. Enzyme selectivity of new cyclooxygenase-2/5 lipoxygenase inhibitors using molecular modeling approach.
Kothekar V; Sahi S; Mishra J
Indian J Biochem Biophys; 2000 Apr; 37(2):86-96. PubMed ID: 10983419
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of subtype-selective cyclooxygenase (COX) inhibitors derived from thalidomide.
Sano H; Noguchi T; Tanatani A; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2005 May; 13(9):3079-91. PubMed ID: 15809144
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
[TBL] [Abstract][Full Text] [Related]
17. A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors.
Aronov AM; Bemis GW
Proteins; 2004 Oct; 57(1):36-50. PubMed ID: 15326593
[TBL] [Abstract][Full Text] [Related]
18. A CoMFA study of COX-2 inhibitors with receptor based alignment.
Datar PA; Coutinho EC
J Mol Graph Model; 2004 Dec; 23(3):239-51. PubMed ID: 15530820
[TBL] [Abstract][Full Text] [Related]
19. Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors.
Rella M; Rushworth CA; Guy JL; Turner AJ; Langer T; Jackson RM
J Chem Inf Model; 2006; 46(2):708-16. PubMed ID: 16563001
[TBL] [Abstract][Full Text] [Related]
20. Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors.
Mizutani MY; Itai A
J Med Chem; 2004 Sep; 47(20):4818-28. PubMed ID: 15369385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
